Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.65 |
| ▸ | PPARG | P37231 | 6/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | YAP1 | P46937 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | LAP3 | P28838 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499760 | 1.00 | LTA4H (0.65) | LTA4HPPARGMMP9MMP8RAB9A | |
| Hydrochloric Acid SCHEMBL29693844 | 0.99 | LTA4H (0.64) | LTA4HPPARGMMP9MMP8RAB9A | |
| SCHEMBL12379283 | 0.97 | LTA4H (0.62) | LTA4HPPARGMMP9MMP8RAB9A | |
| SCHEMBL23901567 | 0.92 | LTA4H (0.61) | LTA4HPPARGMMP9MMP8MME | |
| SCHEMBL13110180 | 0.89 | LTA4H (0.65) | LTA4HPPARGMMP9MMP8RAB9A | |
| SCHEMBL2030203 | 0.89 | PPARG (0.67) | LTA4HPPARGMMP9MMP8MME | |
| SCHEMBL2035189 | 0.89 | PPARG (0.67) | LTA4HPPARGMMP9MMP8MME | |
| SCHEMBL8760872 | 0.89 | PPARG (0.67) | LTA4HPPARGMMP9MMP8MME | |
| SCHEMBL13013217 | 0.88 | PPARG (0.62) | LTA4HPPARGMMP9MMP8MME | |
| SCHEMBL13227760 | 0.88 | PPARG (0.62) | LTA4HPPARGMMP9MMP8MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358989-B2 | Apratyramide therapeutic agents and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200361995-A1 | APRATYRAMIDE THERAPEUTIC AGENTS AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| WO-2019104200-A1 | APRATYRAMIDE THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | LTA4H 1788/4885PPARG 189/4885MMP9 4426/4885 |
| US-20200361995-A1 | APRATYRAMIDE THERAPEUTIC AGENTS AND METHODS OF TREATMENT | FAP, STAT6, DNPEP | LTA4H 93/4885PPARG 533/4885MMP9 216/4885 |
| US-11358989-B2 | Apratyramide therapeutic agents and methods of treatment | FAP, STAT6, DNPEP | LTA4H 93/4885PPARG 533/4885MMP9 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.